We are conducting a clinical trial to investigate the use of duloxetine as a treatment for chemotherapy-induced peripheral neuropathy (CIPN).
Duloxetine is currently available for use in Australia as an antidepressant. It is safe and used by many people in the general community, with minimal side effects. Recent studies have found that duloxetine may also be useful as a treatment for CIPN, reducing painful symptoms. Our trial aims to provide further evidence regarding duloxetine’s effect on CIPN. Unlike previous studies, our trial will directly measure nerve function, using state of the art non-invasive methods to assess the impact of duloxetine on nerves.
To take part in the study, you must be at least 18 years old, and have completed chemotherapy treatment. You also must have experienced symptoms of CIPN on a daily basis for at least 3 months after completing chemotherapy.
The clinical trial consists of two phases: a phase where participants receive duloxetine, and another phase where they receive a placebo. You will receive duloxetine if you take part in this trial.
Please feel free to get in touch with us to discuss taking part in the trial.